Recent

% | $
Quotes you view appear here for quick access.

Facebook, Inc. (FB) Message Board

garysnoop1 92 posts  |  Last Activity: Sep 21, 2016 4:44 PM Member since: Oct 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Inner-Knowledge people..(how's that for political correctness )

  • Wonder what that bodes for us if anything..

    Sentiment: Strong Buy

  • I have 3 computers and cant get a decent response on this board from yahoo. It's like it's running at half speed,does any one else have this problem or is it my broken down internet company..

  • Or is this all you got..Sad..,you knock ino but don't leave..humm. Some day wou'll be able to own INO..but NOT at .10 a post..Don't you guys have a union ??

  • Reply to

    Ya gota' read this..

    by garysnoop1 Sep 12, 2016 10:07 AM
    garysnoop1 garysnoop1 Sep 13, 2016 8:57 AM Flag

    Any port in a storm...

  • Reply to

    Ya gota' read this..

    by garysnoop1 Sep 12, 2016 10:07 AM
    garysnoop1 garysnoop1 Sep 12, 2016 4:21 PM Flag

    About time..

  • garysnoop1 by garysnoop1 Sep 12, 2016 10:07 AM Flag

    Sept. 12, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (INO) today announced that its Zika vaccine in development has been named a 2016 Technology Breakthrough by the editors of Popular Mechanics magazine, the leading technology voice in the U.S. with millions of readers.

    Inovio has advanced its DNA-based Zika vaccine into two trials in the U.S., Canada and Puerto Rico. Inovio expects to have results before the end of this year for its U.S. study. In addition, the CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for Inovio’s Zika vaccine and this study’s placebo control design to provide exploratory signals of vaccine efficacy. The company expects to meet with regulators next year to determine the most efficient path forward to develop its Zika vaccine and help mitigate this widespread Zika outbreak that has now expanded into the continental United States.

    In selecting Inovio’s Zika vaccine as a 2016 breakthrough technology the magazine cited: “Inovio Pharmaceuticals, the drug company behind what looks to become the fastest vaccine ever to come to market, may be able to halt such a (Zika) spread before it gets out of control. The company shocked the medical world in June by announcing that its Zika vaccine had already received FDA approval for human clinical trials, just nine months after the race to prevent Zika began. If all goes well, its shot will be available to the public as soon as early 2018.”

    Dr. J. Joseph Kim, Inovio’s President & CEO, said, “This award recognizes the Inovio scientists and engineers who have advanced Inovio’s Zika vaccine into two human studies. Inovio was the first to manufacture a Zika vaccine, the first to begin human trials and we expect to have the first human trials data late this year.”

    Inovio is developing its Zika vaccine, GLS-5700, with GeneOne Life Science, Inc. (011000.KS) and academic collaborators from the US and Canada who are also working to advance Inovio’s Ebola and MERS vaccines through clinical development.

    There are no approved vaccines or therapies for Zika virus infection. While multiple companies and academic groups have announced development plans for Zika virus vaccines, only Inovio and a US government research center have started human clinical studies.

  • Reply to

    Deleated..what happened to freedom of speach?

    by garysnoop1 Sep 2, 2016 1:59 PM
    garysnoop1 garysnoop1 Sep 4, 2016 9:32 AM Flag

    Yascrew wouldn't post it here ,so I did the news on the new board..Yadumb is a really screwed up outfit..

  • go to the new... board

  • Reply to

    GeneOne..

    by garysnoop1 Aug 31, 2016 4:24 PM
    garysnoop1 garysnoop1 Sep 1, 2016 12:26 PM Flag

    For the ones that dont get it,..

  • PLYMOUTH MEETING, Pa. – August 29, 2016 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.

    Dr. J. Joseph Kim, Inovio’s President & CEO, said, “The rapid progression of the Zika outbreak in Puerto Rico provides an immediate and unique opportunity to assess a preventive vaccine in a real world setting. Inovio and its collaborators are moving ahead with this second Zika vaccine clinical trial to evaluate safety, immune responses, and possible signals of vaccine efficacy. If the results are promising, we plan to meet with regulators in 2017 to map out the most efficient path forward to develop our Zika vaccine and help mitigate this widespread Zika outbreak that has expanded into the continental United States.”

    Inovio is developing its Zika vaccine, GLS-5700, with GeneOne Life Science, Inc. (KSE: 011000) and academic collaborators from the US and Canada who are also working to advance Inovio’s Ebola and MERS vaccines through clinical development.

    In June, Inovio was the first to commence a human Zika trial, with sites in the U.S. and Canada. All 40 subjects for the first clinical study have been fully enrolled and dosed. Inovio expects to report results before the end of this year.

    There are no approved vaccines or therapies for Zika virus infection. While multiple companies and academic groups have announced development plans for Zika virus vaccines, only Inovio and a US government research center have started human clinical studies.

    Inovio’s second clinical study is a placebo-controlled, double-blind trial involving 160 healthy adult volunteers (80 subjects will receive vaccine and 80 subjects will receive placebo) to evaluate the safety, tolerability and immunogenicity of GLS-5700 administered with Inovio’s CELLECTRA®-3P device. This proprietary intradermal DNA vaccine delivery device has been shown to maximize antigen expression and immune responses in multiple human studies. Inovio will also assess differences in Zika infection rates in participants given either placebo or vaccine as part of an exploratory endpoint. In preclinical testing, this synthetic vaccine induced robust antibody and T cell responses - the immune responses necessary to fight viral infections - in small and large animal models.

  • PLYMOUTH MEETING, Pa. – August 29, 2016 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.

    Dr. J. Joseph Kim, Inovio’s President & CEO, said, “The rapid progression of the Zika outbreak in Puerto Rico provides an immediate and unique opportunity to assess a preventive vaccine in a real world setting. Inovio and its collaborators are moving ahead with this second Zika vaccine clinical trial to evaluate safety, immune responses, and possible signals of vaccine efficacy. If the results are promising, we plan to meet with regulators in 2017 to map out the most efficient path forward to develop our Zika vaccine and help mitigate this widespread Zika outbreak that has expanded into the continental United States.”

    Inovio is developing its Zika vaccine, GLS-5700, with GeneOne Life Science, Inc. (KSE: 011000) and academic collaborators from the US and Canada who are also working to advance Inovio’s Ebola and MERS vaccines through clinical development.

    In June, Inovio was the first to commence a human Zika trial, with sites in the U.S. and Canada. All 40 subjects for the first clinical study have been fully enrolled and dosed. Inovio expects to report results before the end of this year.

    There are no approved vaccines or therapies for Zika virus infection. While multiple companies and academic groups have announced development plans for Zika virus vaccines, only Inovio and a US government research center have started human clinical studies.

    Inovio’s second clinical study is a placebo-controlled, double-blind trial involving 160 healthy adult volunteers (80 subjects will receive vaccine and 80 subjects will receive placebo) to evaluate the safety, tolerability and immunogenicity of GLS-5700 administered with Inovio’s CELLECTRA®-3P device. This proprietary intradermal DNA vaccine delivery device has been shown to maximize antigen expression and immune responses in multiple human studies. Inovio will also assess differences in Zika infection rates in participants given either placebo or vaccine as part of an exploratory endpoint. In preclinical testing, this synthetic vaccine induced robust antibody and T cell responses - the immune responses necessary to fight viral infections - in small and large animal models.

  • garysnoop1 by garysnoop1 Aug 31, 2016 4:24 PM Flag

    About GeneOne Life Science

    GeneOne Life Science, Inc. is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for preclinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. VGXI manufactured the Zika vaccine and other emerging disease vaccines including Ebola and MERS

  • Reply to

    Where are the Inovio news?

    by bballgm Aug 31, 2016 2:05 PM
    garysnoop1 garysnoop1 Aug 31, 2016 3:17 PM Flag

    I hope the low hanging fruit isn't makes wine,not vinigar !!

  • The study will evaluate safety, immunogenicity and early signs of efficacy in preventing Zika infection. Data are expected in 2017, and if positive, Inovio will discuss with regulators the best path forward.
    In addition, the phase I study of GLS-5700 (N=40) in the U.S. and Canada, which is the first in-human Zika vaccine study, is now fully enrolled. Data evaluating safety and immunogenicity are expected by YE16.
    Conclusion. With the Zika virus spreading, including to the U.S., there remains an urgent need for a vaccine. Inovio continues to demonstrate that the company’s

  • garysnoop1 by garysnoop1 Aug 29, 2016 11:22 AM Flag

    Inovio Pharmaceuticals, Inc. (Nasdaq: INO) announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.

    Dr. J. Joseph Kim, Inovio’s President & CEO, said, “The rapid progression of the Zika outbreak in Puerto Rico provides an immediate and unique opportunity to assess a preventive vaccine in a real world setting. Inovio and its collaborators are moving ahead with this second Zika vaccine clinical trial to evaluate safety, immune responses, and possible signals of vaccine efficacy. If the results are promising, we plan to meet with regulators in 2017 to map out the most efficient path forward to develop our Zika vaccine and help mitigate this widespread Zika outbreak that has expanded into the continental United States.”

  • Inovio completed end-of-Phase 2 meetings with both the FDA and European Medicines Agency (EMA) back in April, with both agencies discussing the development plan of the firm’s pipeline drug, VGX-3100, a therapeutic synthetic DNA vaccine treatment targeting cervical dysplasia caused by the human papillomavirus (HPV). Aschoff finds Inovio “on track” to initiate a Phase 3 trial in its fourth quarter following affirmative opinions from the FDA and EMA on the pipeline.

    INO’s commercial design for the intramuscular immunotherapy delivery to be administered for the Phase 3 trial has been finalized, with the firm to reveal the official design plans at initiation. Aschoff notes that Inovio’s fourth quarter will include several clinical read-outs that will prove significant, from its multi-center Phase 1 Zika virus vaccine (GLS-5700) trial, designed to treat the major ongoing epidemic in North and South America causing devastating birth defects. Interim immune response and safety data for the vaccine will be forthcoming. Additionally due for fourth-quarter are results for INO-3112, in Phase 1 to test HPV immunotherapy in head and neck cancer.

    The analyst notes, “Inovio and GeneOne Life Science completed enrollment of 75 healthy volunteers in the Phase 1 trial of their GLS-5300 MERS vaccine, with interim data expected in 4Q16. Interim results are also expected in 4Q16 from the Phase 1 trial of INO-5150 for prostate cancer targeting PSMA and PSA, now fully enrolled. Inovio ended 2Q16 with $134.5 million in cash, which should be sufficient to support its operations into 2018, including the $80 million in costs associated with the Phase 3 trial of VGX-3100.”

    Overall, Aschoff remains bullish on Inovio’s clinical progress. Looking into the next quarter, the analyst believes, “We expect Inovio to combine this newly acquired technology with its current electroporation devices and optimize its delivery device in the long run.”

  • garysnoop1 by garysnoop1 Aug 11, 2016 8:58 AM Flag

    Rodman & Renshaw’s Ram Selvaraju weighed in on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO), after the company reported second-quarter results. With pipeline drug approval within reach, a new Phase 3 study starting soon, and a strategy bolstered by three drug candidates, Selvaraju reiterates a Buy on INO with a $17 price target, marking a nearly 93% increase from where the stock is currently trading.

    Worthy of note, management has discussed the affirmative path provided by both the FDA and the European Medicines Agency (EMA) for its pipeline drug VGX-3100 to treat HPV-16/18-related high grade cervical dysplasia in a pivotal Phase 3 registration study. After having both completion of commercial device design for the drug as well as manufacturing process development efforts underway, the drug maker is in prep mode for submitting the final package to the FDA in the upcoming weeks, with full expectation for first dosing to commence by fourth quarter.

    Management has also discussed that this Phase 3 trial will likely enroll around 350 patients at 150 sites worldwide, with a similar efficacy endpoint to that in the Phase 2 study. Selvaraju comments, “This is encouraging news, in our view, together with the fact that it has been 1.5 years since 160 patients received their first dosing of VGX-3100 in the Phase 2 study and no significant adverse events have been observed thus far.”
    Another positive factor weighing in INO’s corner is the presentation of a new plan called Inovio Vision 2020, set to have three drug candidates ready for registration in 2020. Of course, not at all surprising to the analyst, the first candidate ready will be VGX-3100. The second one will be a cancer-treating candidate, potentially new candidate, INO-5400, a multi-antigen immunotherapy to be used in combination with checkpoint inhibitors.

    Meanwhile, Inovio’s PENNVAX®-GP HIV immunotherapy is set to deliver Phase 1 data by 1H 2017. Selvaraju believes, “These data readouts in the coming quarters could drive further upside in the stock, in our view.”

    Additionally, Inovio’s total revenue for the quarter was $6.2 million, above Selvaraju’s projection, which the analyst attributes to a surge in development payments from the firm’s DARPA Ebola grant. The company saw a net loss of $18.7 million during the quarter, or ($0.26) per share.

    TipRanks analytics exhibit INO as a Strong Buy. Based on 4 analysts polled in the last 3 months, 3 rate a Buy on the stock and 1 maintains a Hold. The consensus price target stands at $17.50, marking a 97% upside from where the shares last closed.

  • garysnoop1 by garysnoop1 Aug 9, 2016 5:12 PM Flag

    Inovio Pharmaceuticals Inc. (NASDAQ:INO) has been assigned a $18.00 target price by equities research analysts at Brean Capital in a report released on Monday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Brean Capital’s price target indicates a potential upside of 92.51% from the stock’s previous close.
    Inovio Pharmaceuticals (NASDAQ:INO) traded down 3.64% on Monday, hitting $9.01. 1,746,943 shares of the stock were exchanged. The company’s 50 day moving average is $9.44 and its 200 day moving average is $8.78. Inovio Pharmaceuticals has a 1-year low of $4.50 and a 1-year high of $11.69. The stock’s market cap is $658.60 million.

    Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.05. During the same period in the previous year, the business earned ($0.09) EPS. The business had revenue of $6.20 million for the quarter, compared to analysts’ expectations of $4.95 million. The firm’s revenue was up 17.0% on a year-over-year basis. On average, equities research analysts expect that Inovio Pharmaceuticals will post ($0.75) earnings per share for the current year.

    In related news, Director Morton Collins bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 28th. The shares were acquired at an average price of $9.13 per share, with a total value of $91,300.00. Following the completion of the transaction, the director now owns 142,291 shares of the company’s stock, valued at approximately $1,299,116.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Simon X. Benito sold 6,250 shares of the business’s stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $10.37, for a total transaction of $64,812.50. Following the transaction, the director now directly owns 24,048 shares in the company, valued at approximately $249,377.76. The disclosure for this sale can be found here.

    A number of large investors have made changes to their positions in INO. Creative Planning raised its stake in shares of Inovio Pharmaceuticals by 10.6% in the first quarter. Creative Planning now owns 170,599 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 16,400 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Inovio Pharmaceuticals by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 13,492 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 1,855 shares during the period. Bellevue Group AG acquired a new stake in shares of Inovio Pharmaceuticals during the first quarter valued at about $2,308,000. BlackRock Group LTD raised its stake in shares of Inovio Pharmaceuticals by 71.1% in the first quarter. BlackRock Group LTD now owns 22,064 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 9,168 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Inovio Pharmaceuticals by 10.3% in the first quarter. Geode Capital Management LLC now owns 481,434 shares of the biopharmaceutical company’s stock valued at $4,193,000 after buying an additional 44,923 shares during the period.

    A number of other analysts have also recently weighed in on INO. Maxim Group restated a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a research note on Tuesday, June 21st. Rodman & Renshaw restated a “buy” rating and issued a $17.00 price objective on shares of Inovio Pharmaceuticals in a research note on Tuesday, June 21st. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Inovio Pharmaceuticals in a research note on Tuesday, June 21st. Stifel Nicolaus restated a “buy” rating and issued a $13.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 9th. Finally, Vetr upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.54 price objective for the company in a research note on Tuesday, April 12th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.39.

    Inovio Pharmaceuticals, Inc (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

FB
127.96-2.12(-1.63%)Sep 23 4:00 PMEDT